29 results
424B3
GRI
GRI Bio Inc
28 Mar 24
Prospectus supplement
4:45pm
and others in the medical community necessary for commercial success.
Even if GRI-0621, GRI-0803 or any other product candidate we develop receives marketing … programs and managed care organizations, and others in the medical community. In addition, the availability of coverage by third-party payors may
424B3
GRI
GRI Bio Inc
28 Mar 24
Prospectus supplement
4:42pm
and others in the medical community necessary for commercial success.
Even if GRI-0621, GRI-0803 or any other product candidate we develop receives marketing … programs and managed care organizations, and others in the medical community. In addition, the availability of coverage by third-party payors may
424B4
GRI
GRI Bio Inc
2 Feb 24
Prospectus supplement with pricing info
4:21pm
marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community … organizations, and others in the medical community. In addition, the availability of coverage by third-party payors may be affected by existing and future
424B3
ts5q6 901o8
15 Dec 23
Prospectus supplement
5:02pm
S-4
EX-10.27
cjmnxafo xuq
23 Dec 22
Registration of securities issued in business combination transactions
6:06am
S-4
EX-10.31
v6t41wz40sw47h0
23 Dec 22
Registration of securities issued in business combination transactions
6:06am
S-4
tw0dtvip
23 Dec 22
Registration of securities issued in business combination transactions
6:06am
S-4
EX-10.25
aafxc7zqc77 t49vbna
23 Dec 22
Registration of securities issued in business combination transactions
6:06am
8-K
EX-2.1
u84kffrtle8j2oh8lx
13 Dec 22
Vallon Pharmaceuticals and GRI Bio Enter into Merger Agreement with Goal of Advancing Innovative Pipeline of NKT Cell Regulators
4:09pm
DEF 14A
r4y4dwgi
27 Apr 22
Definitive proxy
4:05pm